Spotlight Innovation Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Spotlight Innovation Inc.
Plus deals involving Ono/PeptiDream, Onconic/Livzon, Teijin/Novartis, Eisai/Biogen, Abbisko/Allist, Daewoong/M8, GC Biopharma/Catalyst and KYM Biosciences/AstraZeneca.
Shionogi is hoping to demonstrate the efficacy of its oral COVID-19 candidate Xocova through an appropriate primary endpoint in its Phase III trial, while the Japanese firm is also eyeing global expansion for the drug should a world-first domestic approval be granted.
Cidara gets $30m up front for US rights to the weekly echinocandin candidate for candidemia and invasive candidiasis. Takeda walks away from oncolytic virus candidate licensed from Turnstone.
This month's roundup also records a second tie-up between Florida State and Spotlight Innovations, while Taiwan's Lin Biosciences licenses global rights to a CDC7 kinase inhibitor from Columbia and Memorial Sloan Kettering.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Celtic Biotech Iowa Inc.
- Memcine Pharmaceuticals Inc.
- American Exploration Corporation
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.